The company has demonstrably advanced this development of an novel therapy for cardiac amyloidosis, leveraging Attruby. Initial patient results reveals potential benefits for individuals suffering from this severe illness. This effort underscores BridgeBio's commitment to treating unmet patient needs in this cardiology space. Attruby: BridgeBio's